Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: A prospective randomized pilot study  by Shimada, Masahiko et al.
Søren Møller
Department of Clinical Physiology,
Faculty of Health Sciences,
Copenhagen University Hospital Hvidovre,
Copenhagen, Denmark
Andrew K. Burroughs
The Royal Free Sheila Sherlock Liver Centre,
Royal Free Hospital,
Royal Free Hampstead NHS Trust and UCL,
London, UK
Flemming Bendtsen
Department of Gastroenterology, Faculty of Health Sciences,
Copenhagen University Hospital Hvidovre,
Copenhagen, Denmark
Pitavastatin enhances antiviral efﬁcacy of standard
pegylated interferon plus ribavirin in patients with chronic
hepatitis C: A prospective randomized pilot study
niﬁcance due to the low number of patients (p = 0.2123). No sig-
niﬁcant differences between those two groups were found in the
rate of adverse drug events. Furthermore, no signiﬁcant
differences were observed in serum AST, ALT, and CK levels
(not shown). There was no case in which the medication had to
be discontinued prematurely due to side effects.
In conclusion, in patients with CHC genotype 1b, the use of
pitavastatin with PEG-IFN plus ribavirin increased the rate of
patients with undetectable HCV viral load. Furthermore, the use
of pitavastatin with PEG-IFN plus ribavirin increased slightly
the SVR (not statistically signiﬁcant). Of note, the addition of pita-
vastatin caused no adverse effects, and treatment could be con-
tinued in all patients within this pilot trial. Therefore, the
addition of pitavastatin to standard antiviral therapy appears to
be a promising option to increase SVR in patients with CHC,
which will justify larger prospective clinical trials.
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Fig. 1. Cumulative rate of HCV patients whose HCV-RNA dropped to
undetectable levels and SVR rates of patients treated with standard PEG-IFN
plus ribavirin with or without pitavastatin. (A) The cumulative rate of patients
in whom HCV-RNA decreased to undetectable levels by PEG-IFN plus ribavirin or
by additional use of pitavastatin (1–2 mg/day) with PEG-IFN plus ribavirin was 5%
and 29% at 4 weeks (p = 0.0408) and 48% and 81% at 12 weeks (p = 0.0259),
respectively. (B) The SVR rate of the group without pitavastatin was 48% while
that of the group with pitavastatin was 67% at 72 weeks (p = 0.2123).
JOURNAL OF HEPATOLOGYTo the Editor:
We read the article by Harrison et al. [1] with great interest. The
authors performed a retrospective analysis of serum cholesterol
and statin use of patients in the IDEAL study. They found a signif-
icantly higher sustained virological response (SVR) among
patients who took a statin prior to antiviral therapy compared
to patients not using statins. However, this was not a prospective
trial and they did not show the combined effect of statins with
PEG-IFN plus ribavirin.
In vitro studies showed antiviral efﬁcacy with statins [2], but
pilot clinical trials showed no or modest beneﬁt [3–5]. Since insu-
lin resistance is increased in chronic hepatitis C infection [6,7]
and also insulin resistance impairs SVR rate to PEG-IFN plus riba-
virin [8]; improvement of insulin resistance with statin might
improve SVR. Pitavastatin is a statin approved in Japan in 2003
[9], and in the US in 2009 [10]. Of note, in vitro studies in the
HCV replicon system showed that pitavastatin reduced viral rep-
lication [11–13]. We performed a prospective, randomized, and
controlled pilot trial of standard PEG-IFN-2b plus ribavirin, with
or without the addition of pitavastatin, to prove if pitavastatin
therapy can enhance virus suppression and elimination.
A total of 42 CHC patients diagnosed with genotype 1b and
with a viral load >5.0 Log IU/ml, who were treated with PEG-
IFN-2b at 1.0–1.5 lg/kg/week, plus ribavirin at 800–1400 mg/
day or 48 weeks were randomly assigned to receiving pitavasta-
tin (1–2 mg/day) or no additional therapy for 48 weeks. Patients
with diabetes mellitus or fatty liver were excluded. No signiﬁcant
difference was observed in the cumulative dose of PEG-IFN and
RBV between the standard and pitavastatin treatment groups.
Viral load was monitored at 4, 8, 12, 24, and 48 weeks after
treatment initiation using TaqMan real-time PCR (BML, Inc.,
Japan, range of quantitation: 1.2–7.8 Log IU/ml). The level of
HCV-RNA, SVR rate, adverse events, serum AST, ALT, and creatine
kinase (CK) were evaluated and compared using the Mann–Whit-
ney U test.
The cumulative rate of patients in whom HCV-RNA became
undetectable by standard combination therapy or standard ther-
apy with added pitavastatin was 5% and 29% at 4 weeks
(p = 0.0408), 33% and 57% at 8 weeks (p = 0.1256), 48% and 81%
at 12 weeks (p = 0.0259), 62% and 86% at 24 weeks (p = 0.0830),
and 67% and 86% at 48 weeks (p = 0.1522), respectively
(Fig. 1A). SVR at 72 weeks was 67% for patients with triple ther-
apy compared to 48% for patients with standard therapy alone
(Fig. 1B). However, this difference did not yet reach statistical sig-Journal of Hepatology 2012 vol. 56 j 298–302 299
Acknowledgments
Contributors: M.S. and S.Y. contributed equally to the manage-
ment of the patient, researching for and writing of this manu-
script. R.M. commented on drafts and did literature searches.
D.S. advised on, wrote, and revised the manuscript. All authors
read and approved the ﬁnal manuscript.
Some aspects of this study were presented at the poster session
of the 61st Annual meeting of the American Association for the
Study of Liver Diseases (AASLD) in Boston, 2010, where it was
awarded with an AASLD Poster Prize.
References
[1] Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum
cholesterol and statin use predict virological response to peginterferon and
ribavirin therapy. Hepatology 2010;52:864–874.
[2] Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV
proﬁles of statins and their potential for combination therapy with
interferon. Hepatology 2006;44:117–125.
[3] O’Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit
antiviral activity against HCV at conventional doses: a pilot clinical trial.
Hepatology 2007;45:895–898.
[4] Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Fluvastatin
inhibits hepatitis C replication in humans. Am J Gastroenterol 2008;103:
1383–1389.
[5] Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Kobayashi M, et al. An open
pilot study exploring the efﬁcacy of ﬂuvastatin, pegylated interferon and
ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
Intervirology 2009;52:43–48.
[6] Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al.
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4,
serum HCV RNA level, and liver ﬁbrosis. Gastroenterology 2008;134:
416–423.
[7] Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic
hepatitis C: why does it really matter? Gut 2006;55:123–130.
[8] Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M,
Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained
response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Gastroenterology 2005;128:636–641.
[9] Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59:
239–252.
[10] Ahmad H, Cheng-Lai A. Pitavastatin: a new HMG-CoA reductase inhibitor for
the treatment of hypercholesterolemia. Cardiol Rev 2010;18:264–267.
[11] Ikeda M, Kato N. Life style-related diseases of the digestive system: cell
culture system for the screening of anti-hepatitis C virus (HCV) reagents:
suppression of HCV replication by statins and synergistic action with
interferon. J Pharmacol Sci 2007;105:145–150.
[12] Moriguchi H, Chung RT, Sato C. An identiﬁcation of the novel combination
therapy for hepatitis C virus 1b infection by using a replicon system and
human induced pluripotent stem cells. Hepatology 2010;51:351–352.
[13] Moriguchi H, Chung RT, Sato C. New translational research on novel drugs
for hepatitis C virus 1b infection by using a replicon system and human
induced pluripotent stem cells. Hepatology 2010;51:344–345, [author reply
345].
Masahiko Shimada
Department of Gastroenterology, Internal Medicine,
TMG Asakadai Central General Hospital, Saitama, Japan
Shuhei Yoshida⇑,
Department of Gastroenterology, Internal Medicine, TMG Asakadai
Central General Hospital, Saitama, Japan
Division of Gastroenterology, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, USA
These authors contributed equally to this work.⇑ Tel.: +1 617 667 8377; fax: +1 617 667 2767.
E-mail addresses: syoshida@bidmc.harvard.edu,
carcinogenesis@hotmail.com
Ryota Masuzaki
Division of Gastroenterology, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, USA
Detlef Schuppan
Division of Gastroenterology, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, USA
Smoking and NASH: A hidden message from the GREACE trial
To the Editor:
The article by Zein et al. in the April issue of this Journal adds to a
growing body of evidence that tobacco use may be linked to pro-
gression of non-alcoholic fatty liver disease (NAFLD) [1]. How-
ever, while there was an association between the degree of
ﬁbrosis and tobacco use among the 1091 patients studied, the
authors mention that they could not, surprisingly, ﬁnd an associ-
ation between NASH and current tobacco use. Another recent
trial may provide some data regarding this.
Athryos and colleagues recently used a post-hoc analysis of
the GREACE trial to demonstrate that statins were safe for use
in patients with elevated liver enzymes and presumed NAFLD
[2]. However, the authors of that trial seem to have overlooked
data that suggest an association between smoking and presumed
NAFLD. A review of the baseline characteristics in the GREACE
trial shows a large difference in the number of current and past
smokers between patients with normal and abnormal liver tests.
Forty six out of 437 patients (10.3%) with abnormal liver tests
were current smokers, as compared to 51/1163 with normal liver
tests (4.4%). In addition, 146/437 (33.4%) with abnormal liver
tests were past smokers as compared to 290/1163 (24.9%) with
normal liver tests.
Using this data, we were able to calculate the odds-ratio (OR)
that a current smoker has abnormal liver tests compared to a life-
time non-smoker to be 3.03 (95% conﬁdence interval 1.98–4.6).
Similarly, the odds-ratio for a past smoker having abnormal liver
tests compared to a lifetime non-smoker is 1.69 (95% conﬁdence
interval 1.32–2.16) and a patient with any history of smoking
developing abnormal liver test is 1.88 (95% conﬁdence interval
1.51–2.37). These data show a higher risk for current smokers
to have abnormal liver tests as compared to past smokers.
The GREACE trial lacked liver biopsies to conﬁrm a diagnosis
of NAFLD, and relied on abnormal liver tests and abdominal ultra-
sound to make a diagnosis of presumed NAFLD. However, the
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